From: T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
BM | PB | |||||
---|---|---|---|---|---|---|
Healthy Median % (IQR) | Myeloma Median % (IQR) | Healthy Median % (IQR) | Myeloma Median % (IQR) | |||
CD4+ T cells | ||||||
CD45RA+/CD62L+ (Tn) | 24.1 (13.2–39.10) | 26.0 (14.5–36.4) | n.s. | 18.1 (14.0–39.8) | 25.7 (14.4–42.9) | n.s. |
CD45RA−/CD62L+ (Tcm) | 44.6 (37.2–48.2) | 35.0 (19.4–52.6) | n.s. | 48.8 (43.3–61.3) | 42.4 (31.6–60.0) | n.s. |
CD45RA−/CD62L− (Tem) | 26.0 (22.1–32.2) | 23.2 (9.2–36.3) | n.s. | 18.7 (13.3–21.8) | 15.6 (9.8–25.9) | n.s. |
CD45RA+/CD62L− (Temra) | 4.5 (2.4–6.2) | 6.2 (2.0–16.8) | n.s. | 2.9 (0.9–3.9) | 2.4 (0.4–7.0) | n.s. |
CD8+ T cells | ||||||
CD45RA+/CD62L+ (Tn) | 11.3 (7.6–18.4) | 18.5 (10.3–24.7) | n.s. | 14.8 (9.2–28.2) | 26.3 (15.7–53.5) | n.s. |
CD45RA−/CD62L+ (Tcm) | 13.2 (9.8–17.1) | 10.2 (7.0–15.3) | n.s. | 23.5 (18.6–34.5) | 19.4 (12.5–36.9) | n.s. |
CD45RA−/CD62L− (Tem) | 49.6 (40.0–66.2) | 27.2 (19.8–38.9) | ** | 30.1 (27.1–44.0) | 18.5 (11.3–32.4) | * |
CD45RA+/CD62L− (Temra) | 18.7 (15.1–27.9) | 34.5 (25.7–52.4) | ** | 19.0 (11.4–32.3) | 20.6 (7.7–31.3) | n.s. |